BBA
CHRS icon

Baader Bank Aktiengesellschaft’s Coherus Oncology CHRS Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,571
Closed -$13.1K – 435
2024
Q4 		$13.1K Buy
+10,571
New +$11.9K ﹤0.01% 369
2024
Q1 		– Sell
-14,020
Closed -$34.6K – 339
2023
Q4 		$34.6K Buy
+14,020
New +$37.6K ﹤0.01% 297

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Baader Bank Aktiengesellschaft's CHRS Position: Q1 2025 in Review

Baader Bank Aktiengesellschaft sold out of Coherus Oncology (CHRS) in Q1 2025, closing a stake of 10,571 shares — an estimated $13.1K sold.

Baader Bank Aktiengesellschaft first reported a position in CHRS in Q4 2023 and held it in 2 quarters. The position peaked at $34.6K in Q4 2023. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2025.

  • Baader Bank Aktiengesellschaft reported no remaining Coherus Oncology position as of Q1 2025 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 10,571 Coherus Oncology shares in Q1 2025, an estimated $13.1K.
  • Baader Bank Aktiengesellschaft first reported a position in Coherus Oncology in Q4 2023 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's Coherus Oncology position peaked at $34.6K in Q4 2023.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2025.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q1 2025, filed 8 May 2025.